Radiation Oncology

Her2-negative breast cancer

Questions discussed in this category

What are your top takeaways in Medical Oncology from SABCS 2024?

13 Answers available

Papers discussed in this category

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2024 Sep 06

Imlunestrant, an Oral Selective Estrogen Receptor Degrader, as Monotherapy and in Combination With Targeted Therapy in Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Phase Ia/Ib EMBER Study.

The New England journal of medicine, 2024 Dec 11

Imlunestrant with or without Abemaciclib in Advanced Breast Cancer.

N. Engl. J. Med.,

Pembrolizumab for Early Triple-Negative Breast Cancer.

Lancet Oncol., 2020 Mar 12

Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): end-of-study results from a double-blind, randomised, placebo-controlled, phase 3 study.

Related Topics in Radiation Oncology